$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
维贝格龙(vibegron)用法用量:推荐剂量及特殊人群剂量调整
2025-10-19 11:44:20
Check Details
维贝格龙(vibegron)的副作用和常见不良反应
2025-10-19 11:44:20
Check Details
维贝格龙(vibegron)详细说明书
2025-10-19 11:44:20
Check Details
维贝格龙(vibegron)中文说明书:适应症、用法用量、剂量调整、不良反应、注意事项
2025-10-19 11:44:20
Check Details
How effective is sparsentan in treating Iga nephropathy?
2025-10-19 11:44:20
Check Details
What are the precautions for using sparsentan?
2025-10-19 11:44:20
Check Details
What are the side effects of sparsentan?
2025-10-19 11:44:20
Check Details
What are the contraindications for sparsentan (which drugs cannot be taken together with it)?
2025-10-19 11:44:20
Check Details
What is the difference between sparsentan and ambrisentan?
2025-10-19 11:44:20
Check Details
What are the effects and functions of sparsentan?
2025-10-19 11:44:20
Check Details
What is the effectiveness of the orphan drug Sparsentan in the treatment of IgA nephropathy?
2025-10-19 11:44:20
Check Details
Does sparsentan have any side effects in treating IgA nephropathy
2025-10-19 11:44:20
Check Details
1
2
...
4201
4202
4203
4204
4205
4206
4207
...
10209
10210
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Odevixibat: Targeting IBAT to Transform Cholestatic Liver Disease Treatment
2
A Precision FGFR Inhibitor for Cholangiocarcinoma
3
A Revolutionary Targeted Therapy for Hematological Malignancies
4
A New Option for Advanced Renal Cell Carcinoma Treatment
5
Trametinib (Mekinist): Precision MEK1/2 Inhibition Transforming Cancer Care Short Description:
6
Pirtobrutinib: A Novel BTK Inhibitor Offering Hope for Hematologic Cancer Patients Short Description:
7
Olaparib Plus Pembrolizumab Maintenance Therapy for Metastatic Pancreatic Cancer: Findings from the POLAR Phase II Basket Trial
8
Sacituzumab Govitecan: Trop-2 Targeted ADC Clinical Medication Guide
9
Fulvestrant (Faslodex) Breast Cancer Guide: Indications, Dosage and Safety Specifications
10
Avatrombopag (Doptelet) Dosage: Dose Adjustment and Medication Guidelines for Different Indications
11
Effects of Gilteritinib (Xospata) Discontinuation in Acute Myeloid Leukemia Treatment
12
Avatrombopag vs Hetrombopag: Full Comparison of TPO Receptor Agonists for Thrombocytopenia